<!DOCTYPE html PUBLIC "-"><html><div class="watermark"/><head><META http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta content="955d6d7d-485f-4b7d-8644-e9933bf35e72" name="documentId"><meta content="3d021d9b-c0b8-41a3-a99b-37f50d2a20ae" name="documentSetId"><meta content="2" name="documentVersionNumber"><meta content="20130516" name="documentEffectiveTime"><title>These highlights do not include all the information needed to use clopidogrel bisulfate safely and effectively. See full prescribing information for clopidogrel tablets, USP.      clopidogrel tablets, USP Initial U.S. Approval: 1997</title><link href="dailymed/fda/spl-.min.css" type="text/css" rel="stylesheet"><script charset="utf-8" type="text/javascript" src="./spl.js">/* */</script><link rel='stylesheet' type='text/css' href='/dailymed/fda/spl-nonquirk-.min.css' /><link rel='stylesheet' type='text/css' href='/dailymed/archives/css/archives-.min.css' /></head><body id="spl" class="spl" onload="if(typeof convertToTwoColumns == &quot;function&quot;)convertToTwoColumns();"><div class="DocumentTitle"><p class="DocumentTitle"><strong>CLOPIDOGREL&nbsp;- clopidogrel bisulfate&nbsp;tablet, film coated&nbsp;</strong><br>Greenstone LLC<br></p><p>----------</p></div><div id="nlmhighlightsmarker"><div class="Highlights" id="Highlights"><table border="0" style="table-layout:fixed" width="100%" cellpadding="5" cellspacing="5"><tr><td valign="top" align="left" width="50%"><div></div></td><td valign="top" align="left" width="50%"><div><h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1><div class="HighlightsDisclaimer">These highlights do not include all the information needed to use clopidogrel bisulfate safely and effectively. See full prescribing information for clopidogrel tablets, USP.<br><br>clopidogrel tablets, USP <br>Initial U.S. Approval: 1997</div><div class="Warning"><div><br><h1 class="Warning"><span class="Bold">WARNING:</span><span class="Bold">DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS</span><br><br><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.<br></span></span>&nbsp;</h1><ul class="Disc"><li><span class="Bold">Effectiveness of clopidogrel bisulfate depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. <a href="#Section_5.1">(5.1)</a></span></li><li><span class="Bold">Poor metabolizers treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function. <a href="#Section_12.4">(12.5)</a></span></li><li><span class="Bold">Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. <a href="#Section_12.4">(12.5)</a></span></li><li><span class="Bold">Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. <a href="#Section_2.4">(2.3</a>, <a href="#Section_5.1">5.1)</a></span></li></ul></div></div><div></div><div class="HighlightSection"><h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1><div><br><p class="Highlights">Clopidogrel tablets, USP&nbsp; </p><span class="Bold"></span><p class="Highlights">are a P2Y<span class="Sub">12</span> platelet inhibitor indicated for:&nbsp;&nbsp;  </p><ul class="Disc"><li>Acute coronary syndrome</li></ul><p class="Highlights">- For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)] including patients who are to be managed medically and those who are to be managed with coronary revascularization, clopidogrel tablets, USP&nbsp;<span class="Bold"></span>have been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. <a href="#Section_1.1">(1.1)</a> </p><p class="Highlights">- For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets, USP&nbsp;<span class="Bold"></span>have been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary PCI is unknown. <a href="#Section_1.1">(1.1)</a> </p><ul class="Disc"><li>Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Clopidogrel tablets, USP&nbsp;<span class="Bold"></span>have been shown to reduce the combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. <a href="#Section_1.2">(1.2)</a></li></ul></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1><div><br><ul class="Disc"><li>Acute coronary syndrome. <a href="#Section_2.1">(2.1)</a></li></ul><br><p class="Highlights">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp; Non-ST-segment elevation ACS (UA/NSTEMI): 300 mg loading dose followed by 75 mg once daily, in combination with aspirin (75 to 325 mg once daily).<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- &nbsp;STEMI: 75 mg once daily, in combination with aspirin (75 to 325 mg once daily), with or without a loading dose and with or without thrombolytics.  </p><ul class="Disc"><li>Recent MI, recent stroke, or established peripheral arterial disease: 75 mg once daily. <a href="#Section_2.2">(2.2)</a></li></ul></div><div></div><div></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1><div><br><p class="Highlights">Tablets: 75 mg <a href="#Section_3">(3)</a> </p></div></div><div class="HighlightSection"><h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1><div><br><ul class="Disc"><li>Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage. <a href="#Section_4.1">(4.1)</a></li><li>Hypersensitivity to clopidogrel or any component of the product. <a href="#Section_4.2">(4.2)</a></li></ul></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1><div><br><ul class="Disc"><li>Reduced effectiveness in impaired CYP2C19 function: Avoid concomitant use with omeprazole or esomeprazole. <a href="#Section_5.1">(5.1)</a>&nbsp;    </li><li>Bleeding: Clopidogrel bisulfate increases risk of bleeding.&nbsp;Discontinue 5 days prior to elective surgery. <a href="#Section_5.2">(5.2)</a></li><li>Discontinuation of Clopidogrel Bisulfate: Premature discontinuation increases risk of cardiovascular events. <a href="#Section_5.3">(5.3)</a></li><li>Recent transient ischemic attack or stroke: Combination use of clopidogrel bisulfate and aspirin in these patients was not shown to be more effective than clopidogrel bisulfate alone, but was shown to increase major bleeding. <a href="#Section_5.4">(5.4)</a></li><li>Thrombotic thrombocytopenic purpura (TTP): TTP has been reported with clopidogrel bisulfate, including fatal cases. <a href="#Section_5.5">(5.5)</a></li></ul></div><div></div><div></div><div></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1><div><br><p class="Highlights">Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction. <a href="#Section_6.1">(6.1)</a><br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Greenstone LLC at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch<span class="Italics">.</span></span> </p><span class="Bold"><span class="Italics"></span></span></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1><div><br><ul class="Disc"><li>Nonsteroidal anti-inflammatory drugs (NSAIDs): Combination use increases risk of gastrointestinal bleeding. <a href="#Section_7.2">(7.2)</a></li><li>Warfarin: Combination use increases risk of bleeding. <a href="#Section_7.3">(7.3)</a></li></ul></div><div></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1><div><br><p class="Highlights">Nursing mothers: Discontinue drug or nursing, taking into consideration importance of drug to mother. <a href="#Section_8.3">(8.3)</a> </p></div><div></div><div></div><div></div><div></div><div></div></div><div></div><div></div><div><div></div><div></div><div></div><div></div></div><div><div></div></div><div><div></div><div></div><div></div></div><div></div><div><div></div><div></div><div></div><div></div><div></div></div><div></div><div></div><p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p><p class="HighlightsRevision">Revised: 05/2013</p></div></td></tr></table></div></div><div class="Index" id="Index"><table border="0" style="table-layout:fixed" width="100%" cellpadding="5" cellspacing="5"><tr><td valign="top" align="left" width="50%"><div></div></td><td valign="top" align="left" width="50%"><div><h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS						<a name="footnote-reference-content" href="#footnote-content">*</a></h1><h1><a href="#section-1" class="toc">WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS</a></h1><h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1><h2><a href="#section-1.1" class="toc">1.1 Acute Coronary Syndrome (ACS)</a></h2><h2><a href="#section-1.2" class="toc">1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease</a></h2><h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1><h2><a href="#section-2.1" class="toc">2.1 Acute Coronary Syndrome</a></h2><h2><a href="#section-2.2" class="toc">2.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease</a></h2><h2><a href="#section-2.3" class="toc">2.3 CYP2C19 Poor Metabolizers</a></h2><h2><a href="#section-2.4" class="toc">2.4 Use with Proton Pump Inhibitors (PPI)</a></h2><h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1><h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1><h2><a href="#section-4.1" class="toc">4.1 Active Bleeding</a></h2><h2><a href="#section-4.2" class="toc">4.2 Hypersensitivity</a></h2><h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1><h2><a href="#section-5.1" class="toc">5.1 Diminished Antiplatelet Activity Due to Impaired CYP2C19 Function</a></h2><h2><a href="#section-5.2" class="toc">5.2 General Risk of Bleeding</a></h2><h2><a href="#section-5.3" class="toc">5.3 Discontinuation of Clopidogrel Bisulfate</a></h2><h2><a href="#section-5.4" class="toc">5.4 Patients with Recent Transient Ischemic Attack (TIA) or Stroke</a></h2><h2><a href="#section-5.5" class="toc">5.5 Thrombotic Thrombocytopenic Purpura (TTP)</a></h2><h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1><h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2><h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2><h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1><h2><a href="#section-7.1" class="toc">7.1 CYP2C19 Inhibitors</a></h2><h2><a href="#section-7.2" class="toc">7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</a></h2><h2><a href="#section-7.3" class="toc">7.3 Warfarin (CYP2C9 Substrates)</a></h2><h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1><h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2><h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2><h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2><h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2><h2><a href="#section-8.5" class="toc">8.6 Renal Impairment</a></h2><h2><a href="#section-8.6" class="toc">8.7 Hepatic Impairment</a></h2><h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1><h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1><h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1><h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2><h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2><h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2><h2><a href="#section-11.4" class="toc">12.5 Pharmacogenomics</a></h2><h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1><h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2><h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1><h2><a href="#section-13.1" class="toc">14.1 Acute Coronary Syndrome</a></h2><h2><a href="#section-13.2" class="toc">14.2 Recent Myocardial Infarction, Recent Stroke, or Established Peripheral Arterial Disease</a></h2><h2><a href="#section-13.3" class="toc">14.3 Lack of Established Benefit of Clopidogrel Bisulfate plus Aspirin in Patients with Multiple Risk Factors or Established Vascular Disease</a></h2><h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1><h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1><h2><a href="#section-15.1" class="toc">17.1 Benefits and Risks</a></h2><h2><a href="#section-15.2" class="toc">17.2 Bleeding</a></h2><h2><a href="#section-15.3" class="toc">17.3 Other Signs and Symptoms Requiring Medical Attention</a></h2><h2><a href="#section-15.4" class="toc">17.4 Invasive Procedures</a></h2><h2><a href="#section-15.5" class="toc">17.5 Concomitant Medications</a></h2><h1><a href="#section-16" class="toc">17.6 Medication Guide</a></h1><h1><a href="#section-17" class="toc">PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 75 mg (90 Tablet Bottle)</a></h1><dl class="Footnote"><dt><a name="footnote-content" href="#footnote-reference-content">*</a></dt><dd>Sections or subsections omitted from the full prescribing information are not listed.</dd></dl></div></td></tr></table></div><div class="Contents"><h1>FULL PRESCRIBING INFORMATION</h1><div class="Section" data-sectionCode="48780-1"><a name="section-1"></a><p></p></div><div class="Warning"><a name="Section_0"></a><a name="section-1"></a><p></p><h1>WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS</h1><br><p class="First"><span class="Bold">The effectiveness of clopidogrel bisulfate is&nbsp;dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>. Clopidogrel&nbsp;</span><span class="Bold">bisulfate at</span>&nbsp;<span class="Bold">recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers.&nbsp; Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate&nbsp;at&nbsp;recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy <span class="Italics">[see <a href="#Section_12.4">Clinical Pharmacology (12.5)</a>]</span>. Consider alternative treatment or treatment strategies&nbsp;in patients identified as CYP2C19 poor metabolizers <span class="Italics">[see <a href="#Section_2.4">Dosage and Administration (2.3)</a>]</span>.</span></p></div><div class="Section" data-sectionCode="34067-9"><a name="Section_1"></a><a name="section-1"></a><p></p><h1>1 INDICATIONS AND USAGE</h1><div class="Section" data-sectionCode="42229-5"><a name="Section_1.1"></a><a name="section-1.1"></a><p></p><h2>1.1 Acute Coronary Syndrome (ACS)</h2><br><ul class="Disc"><li>For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, clopidogrel tablets, USP&nbsp;have been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.    </li><li>For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets, USP&nbsp;have been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary percutaneous coronary intervention is unknown.</li></ul><p class="First">The optimal duration of clopidogrel tablets, USP&nbsp;therapy in ACS is unknown.</p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_1.2"></a><a name="section-1.2"></a><p></p><h2>1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease</h2><br><p class="First">For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, clopidogrel tablets, USP&nbsp;have been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.</p></div></div><div class="Section" data-sectionCode="34068-7"><a name="Section_2"></a><a name="section-2"></a><p></p><h1>2 DOSAGE AND ADMINISTRATION</h1><div class="Section" data-sectionCode="42229-5"><a name="Section_2.1"></a><a name="section-2.1"></a><p></p><h2>2.1 Acute Coronary Syndrome</h2><br><p class="First">Clopidogrel tablets&nbsp;can be administered with or without food <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p><br><ul class="Disc"><li>For patients with non-ST-elevation ACS (UA/NSTEMI), initiate clopidogrel tablets&nbsp;with a single 300 mg oral loading dose and then continue at 75 mg once daily.&nbsp;Initiate aspirin (75 to 325 mg once daily) and continue in combination with clopidogrel tablets&nbsp;<span class="Italics">[see <a href="#Section_14.1">Clinical Studies (14.1)</a>]</span>.    </li><li>For patients with STEMI, the recommended dose of clopidogrel tablet is 75 mg once daily orally, administered in combination with aspirin (75 to 325 mg once daily), with or without thrombolytics. Clopidogrel tablets&nbsp;may be initiated with or without a loading dose <span class="Italics">[see <a href="#Section_14.1">Clinical Studies (14.1)</a>]</span>. </li></ul></div><div class="Section" data-sectionCode="42229-5"><a name="Section_2.2"></a><a name="section-2.2"></a><p></p><h2>2.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease</h2><br><p class="First">The recommended daily dose of clopidogrel tablet is 75 mg once daily orally, with or without food <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_2.3"></a><a name="section-2.3"></a><p></p><h2>2.3 CYP2C19 Poor Metabolizers</h2><br><p class="First">CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel.&nbsp;Although a higher dose regimen in poor metabolizers increases antiplatelet response <span class="Italics">[see <a href="#Section_12.4">Clinical Pharmacology (12.5)</a>]</span>, an appropriate dose regimen for this patient population has not been established.</p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_2.4"></a><a name="section-2.4"></a><p></p><h2>2.4 Use with Proton Pump Inhibitors (PPI)</h2><br><p class="First" style="border-left:1px solid;">Avoid using omeprazole <span class="XmChange"><span class="XmChange"><span class="XmChange">or</span></span></span> esomeprazole with clopidogrel tablets. Omeprazole and esomeprazole significantly reduce the antiplatelet activity of clopidogrel tablets. When concomitant administration of a PPI is required, consider using another acid-reducing agent with minimal or no CYP2C19 inhibitory effect on the formation of clopidogrel active metabolite <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>, <a href="#Section_7.1">Drug Interactions (7.1)</a> and <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p></div></div><div class="Section" data-sectionCode="43678-2"><a name="Section_3"></a><a name="section-3"></a><p></p><h1>3 DOSAGE FORMS AND STRENGTHS</h1><ul class="Disc"><li>75 mg tablets: Pink colored, round, biconvex, beveled edge, film-coated tablets debossed with &lsquo;E&rsquo; on one side and &lsquo;34&rsquo; on the other side.</li></ul></div><div class="Section" data-sectionCode="34070-3"><a name="Section_4"></a><a name="section-4"></a><p></p><h1>4 CONTRAINDICATIONS</h1><div class="Section" data-sectionCode="42229-5"><a name="Section_4.1"></a><a name="section-4.1"></a><p></p><h2>4.1 Active Bleeding</h2><br><p class="First">Clopidogrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage.</p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_4.2"></a><a name="section-4.2"></a><p></p><h2>4.2 Hypersensitivity</h2><br><p class="First">Clopidogrel tablets are contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to clopidogrel or any component of the product <span class="Italics">[see <a href="#Section_6.2">Adverse Reactions (6.2)</a>]</span>.</p></div></div><div class="Section" data-sectionCode="43685-7"><a name="Section_5"></a><a name="section-5"></a><p></p><h1>5 WARNINGS AND PRECAUTIONS</h1><div class="Section" data-sectionCode="42229-5"><a name="Section_5.1"></a><a name="section-5.1"></a><p></p><h2>5.1 Diminished Antiplatelet Activity Due to Impaired CYP2C19 Function</h2><br><p class="First" style="border-left:1px solid;">Clopidogrel <span class="XmChange"><span class="XmChange"><span class="XmChange">is</span></span></span> a prodrug. Inhibition of platelet aggregation by clopidogrel is achieved through an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 <span class="Italics">[see <a href="#Section_0">Boxed Warning</a>] </span>and by concomitant medications that interfere with CYP2C19.&nbsp;<br><span class="Italics"><br>Proton Pump Inhibitors<br>&nbsp;<br></span>Avoid concomitant use <span class="XmChange"><span class="XmChange"><span class="XmChange">of</span></span></span> clopidogrel bisulfate with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of clopidogrel bisulfate<span class="Italics"> [see <a href="#Section_7.1">Drug Interactions (7.1)</a> and <a href="#Section_2.4">Dosage and Administration (2.4)</a>].</span></p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_5.2"></a><a name="section-5.2"></a><p></p><h2>5.2 General Risk of Bleeding</h2><br><p class="First">Thienopyridines, including clopidogrel bisulfate, increase the risk of bleeding. If a patient is to undergo surgery and an antiplatelet effect&nbsp;is not desired, discontinue clopidogrel bisulfate&nbsp;five days prior to surgery. In patients who stopped therapy more than five days prior to CABG the rates of major bleeding were similar (event rate 4.4% clopidogrel bisulfate + aspirin; 5.3% placebo + aspirin).&nbsp;In patients who remained on therapy within five days of CABG, the major bleeding rate was 9.6% for clopidogrel bisulfate + aspirin, and 6.3% for placebo + aspirin.<br><br>Thienopyridines inhibit platelet aggregation for the lifetime of the platelet (7 to 10 days), so withholding a dose will&nbsp;not be useful in managing a bleeding event or the risk of bleeding associated with an invasive procedure. Because the half-life of clopidogrel&rsquo;s active metabolite is short, it may be possible to restore hemostasis by administering exogenous platelets; however, platelet transfusions within 4 hours of the loading dose or 2 hours of the maintenance dose may be less effective.</p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_5.4"></a><a name="section-5.3"></a><p></p><h2>5.3 Discontinuation of Clopidogrel Bisulfate</h2><br><p class="First">Avoid lapses in therapy, and if clopidogrel bisulfate must be temporarily discontinued, restart as soon as possible. Premature discontinuation of clopidogrel bisulfate may increase the risk of cardiovascular events.</p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_5.5"></a><a name="section-5.4"></a><p></p><h2>5.4 Patients with Recent Transient Ischemic Attack (TIA) or Stroke</h2><br><p class="First">In patients with recent TIA or stroke who are at high risk for recurrent ischemic events, the combination of aspirin and clopidogrel bisulfate has not been shown to be more effective than clopidogrel bisulfate alone, but the combination has been shown to increase major bleeding.</p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_5.6"></a><a name="section-5.5"></a><p></p><h2>5.5 Thrombotic Thrombocytopenic Purpura (TTP)</h2><br><p class="First">TTP, sometimes fatal, has been reported following use of clopidogrel bisulfate, sometimes after a short exposure (&lt;2 weeks). TTP is a serious condition that requires urgent treatment including plasmapheresis (plasma exchange). It is characterized by thrombocytopenia, microangiopathic hemolytic anemia (schistocytes [fragmented RBCs] seen on peripheral smear), neurological findings, renal dysfunction, and fever <span class="Italics">[see <a href="#Section_6.2">Adverse Reactions (6.2)</a>].</span></p></div></div><div class="Section" data-sectionCode="34084-4"><a name="Section_6"></a><a name="section-6"></a><p></p><h1>6 ADVERSE REACTIONS</h1><br><p class="First">The following serious adverse reactions are discussed below and elsewhere in the labeling:</p><br><ul class="Disc"><li>Bleeding <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>] </span></li><li>Thrombotic thrombocytopenic purpura <span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>]</span></li></ul><div class="Section" data-sectionCode="42229-5"><a name="Section_6.1"></a><a name="section-6.1"></a><p></p><h2>6.1 Clinical Studies Experience</h2><br><p class="First">Because clinical trials are conducted under widely varying conditions and durations of follow-up, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<br><br>Clopidogrel bisulfate has been evaluated for safety in more than 54,000 patients, including over 21,000 patients treated for 1 year or more. The clinically important adverse reactions observed in trials comparing clopidogrel bisulfate plus aspirin to placebo plus aspirin and trials comparing clopidogrel bisulfate alone to aspirin alone are discussed below.<span class="Italics"><br><br><span class="Underline">Bleeding</span></span><br><span class="Italics"><br>CURE</span><br><br>In CURE, clopidogrel bisulfate use with aspirin was associated with an increase in major bleeding (primarily gastrointestinal and at puncture sites) compared to placebo with aspirin (see Table 1). The incidence of intracranial hemorrhage (0.1%) and fatal bleeding (0.2%) were the same in both groups. Other bleeding events that were reported more frequently in the clopidogrel group were epistaxis, hematuria, and bruise.<br><br>The overall incidence of bleeding is described in Table 1.</p><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><caption><span>Table 1: CURE Incidence of Bleeding Complications (% patients) 			</span></caption><thead><tr class="First Last"><th class="Lrule Rrule Toprule" align="center">Event</th><th class="Lrule Rrule Toprule" align="center">Clopidogrel<br>Bisulfate<br>(+ aspirin)*<br>(n=6259)</th><th class="Lrule Rrule Toprule" align="center">Placebo<br>(+ aspirin)*<br>(n=6303)</th></tr></thead><tfoot><tr class="First Last"><td colspan="3">* Other standard therapies were used as appropriate. <br><span class="Sup">&dagger;</span> Life-threatening and other major bleeding. <br><span class="Sup">&Dagger;</span> Major bleeding event rate for clopidogrel bisulfate + aspirin was dose-dependent on aspirin: &lt;100 mg = 2.6%; 100 to 200 mg = 3.5%; &gt;200 mg = 4.9%. <br>Major bleeding event rates for clopidogrel bisulfate + aspirin by age were: &lt;65 years = 2.5%, &ge;65 to &lt;75 years = 4.1%, &ge;75 years = 5.9%. <br><span class="Sup">&sect;</span> Major bleeding event rate for placebo + aspirin was dose-dependent on aspirin: &lt;100 mg = 2%; 100 to 200 mg = 2.3%; &gt;200 mg = 4%. <br>Major bleeding event rates for placebo + aspirin by age were: &lt;65 years = 2.1%, &ge;65 to &lt;75 years = 3.1%, &ge;75 years = 3.6%. <br><span class="Sup">&para;</span> Led to interruption of study medication. <br></td></tr></tfoot><tbody><tr class="Botrule First"><td class="Lrule Rrule" valign="top">&nbsp;Major bleeding<span class="Sup">&dagger;</span><br></td><td class="Rrule" align="center" valign="top">3.7<span class="Sup">&Dagger;</span><br></td><td class="Rrule" align="center" valign="top">2.7<span class="Sup">&sect;</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp; Life-threatening bleeding<br></td><td class="Rrule" align="center" valign="top">2.2<br></td><td class="Rrule" align="center" valign="top">1.8<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatal<br></td><td class="Rrule" align="center" valign="top">0.2<br></td><td class="Rrule" align="center" valign="top">0.2<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 g/dL hemoglobin drop<br></td><td class="Rrule" align="center" valign="top">0.9<br></td><td class="Rrule" align="center" valign="top">0.9<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Requiring surgical intervention<br></td><td class="Rrule" align="center" valign="top">0.7<br></td><td class="Rrule" align="center" valign="top">0.7<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hemorrhagic strokes<br></td><td class="Rrule" align="center" valign="top">0.1<br></td><td class="Rrule" align="center" valign="top">0.1<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Requiring inotropes<br></td><td class="Rrule" align="center" valign="top">0.5<br></td><td class="Rrule" align="center" valign="top">0.5<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Requiring transfusion (&ge;4 units)<br></td><td class="Rrule" align="center" valign="top">1.2<br></td><td class="Rrule" align="center" valign="top">1<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp; Other major bleeding<br></td><td class="Rrule" align="center" valign="top">1.6<br></td><td class="Rrule" align="center" valign="top">1<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Significantly disabling<br></td><td class="Rrule" align="center" valign="top">0.4<br></td><td class="Rrule" align="center" valign="top">0.3<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intraocular bleeding with<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; significant loss of vision <br></td><td class="Rrule" align="center" valign="top">0.05<br></td><td class="Rrule" align="center" valign="top">0.03<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Requiring 2 to 3 units of blood<br></td><td class="Rrule" align="center" valign="top">1.3<br></td><td class="Rrule" align="center" valign="top">0.9<br></td></tr><tr class="Last"><td class="Lrule Rrule" valign="top">&nbsp;Minor bleeding <span class="Sup">&para;</span><br></td><td class="Rrule" align="center" valign="top">5.1<br></td><td class="Rrule" align="center" valign="top">2.4<br></td></tr></tbody></table><p>Ninety-two percent (92%) of the patients in the CURE study received heparin or low molecular weight heparin (LMWH), and the rate of bleeding in these patients was similar to the overall results.<br><span class="Italics"><br>COMMIT</span><br><br>In COMMIT, similar rates of major bleeding were observed in the clopidogrel bisulfate and placebo groups, both of which also received aspirin (see Table 2). </p><br><br><table border="0" cellpadding="0" cellspacing="0" width="596"><caption><span>Table 2: Incidence of Bleeding Events in COMMIT (% patients) 			</span></caption><thead><tr class="First Last"><th class="Lrule Rrule Toprule" align="center">Type of bleeding</th><th class="Lrule Rrule Toprule" align="center">Clopidogrel Bisulfate<br>(+ aspirin)<br>(n=22961)</th><th class="Lrule Rrule Toprule" align="center">Placebo<br>(+ aspirin)<br>(n=22891)</th><th class="Lrule Rrule Toprule" align="center">p-value</th></tr></thead><tfoot><tr class="First Last"><td colspan="4">* Major bleeds were cerebral bleeds or non-cerebral bleeds thought to have caused death or that required transfusion. <br>** The relative rate of major noncerebral or cerebral bleeding was independent of age. Event rates for clopidogrel bisulfate + aspirin by age were: &lt;60 years = 0.3%, &ge;60 to &lt;70 years = 0.7%, &ge;70 years = 0.8%. Event rates for placebo + aspirin by age were: &lt;60 years = 0.4%, &ge;60 to &lt;70 years = 0.6%, &ge;70 years = 0.7%. <br></td></tr></tfoot><tbody><tr class="Botrule First"><td class="Lrule Rrule" valign="top">&nbsp;Major* noncerebral or cerebral bleeding**<br></td><td class="Rrule" align="center" valign="top">0.6<br></td><td class="Rrule" align="center" valign="top">0.5<br></td><td class="Rrule" align="center" valign="top">0.59<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Major noncerebral<br></td><td class="Rrule" align="center" valign="top">0.4<br></td><td class="Rrule" align="center" valign="top">0.3<br></td><td class="Rrule" align="center" valign="top">0.48<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatal<br></td><td class="Rrule" align="center" valign="top">0.2<br></td><td class="Rrule" align="center" valign="top">0.2<br></td><td class="Rrule" align="center" valign="top">0.9<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;Hemorrhagic stroke <br></td><td class="Rrule" align="center" valign="top">0.2<br></td><td class="Rrule" align="center" valign="top">0.2<br></td><td class="Rrule" align="center" valign="top">0.91<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp; Fatal <br></td><td class="Rrule" align="center" valign="top">0.2<br></td><td class="Rrule" align="center" valign="top">0.2<br></td><td class="Rrule" align="center" valign="top">0.81<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;Other noncerebral bleeding (non-major) <br></td><td class="Rrule" align="center" valign="top">3.6<br></td><td class="Rrule" align="center" valign="top">3.1<br></td><td class="Rrule" align="center" valign="top">0.005<br></td></tr><tr class="Last"><td class="Lrule Rrule" valign="top">&nbsp;Any noncerebral bleeding <br></td><td class="Rrule" align="center" valign="top">3.9<br></td><td class="Rrule" align="center" valign="top">3.4<br></td><td class="Rrule" align="center" valign="top">0.004<br></td></tr></tbody></table><p><span class="Italics">CAPRIE (Clopidogrel </span><span class="Italics">Bisulfate </span><span class="Italics">vs. Aspirin)</span><br><br>In CAPRIE, gastrointestinal hemorrhage occurred at a rate of 2% in those taking clopidogrel bisulfate vs. 2.7% in those taking aspirin; bleeding requiring hospitalization occurred in 0.7% and 1.1%, respectively. The incidence of intracranial hemorrhage was 0.4% for clopidogrel bisulfate compared to 0.5% for aspirin.<br><br>Other bleeding events that were reported more frequently in the clopidogrel bisulfate group were epistaxis and hematoma.<br><span class="Italics"><br><span class="Underline">Other Adverse Events</span></span><br><br>In CURE and CHARISMA, which compared clopidogrel bisulfate plus aspirin to aspirin alone, there was no difference in the rate of adverse events (other than bleeding) between clopidogrel bisulfate and placebo.<br><br>In CAPRIE, which compared clopidogrel bisulfate to aspirin, pruritus was more frequently reported in those taking clopidogrel bisulfate. No other difference in the rate of adverse events (other than bleeding) was reported.</p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_6.2"></a><a name="section-6.2"></a><p></p><h2>6.2 Postmarketing Experience</h2><br><p class="First">The following adverse reactions have been identified during post-approval use of clopidogrel bisulfate. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<br>&nbsp;&nbsp; </p><ul class="Disc"><li><span class="Italics">Blood and lymphatic system disorders:</span> Agranulocytosis, aplastic anemia/pancytopenia, thrombotic thrombocytopenic purpura (TTP)</li><li><span class="Italics">Eye disorders</span>: Eye (conjunctival, ocular, retinal) bleeding&nbsp;&nbsp;</li><li><span class="Italics">Gastrointestinal disorders:</span> Gastrointestinal and retroperitoneal hemorrhage with fatal outcome, colitis (including ulcerative or lymphocytic colitis), pancreatitis, stomatitis, gastric/duodenal ulcer, diarrhea&nbsp;&nbsp;</li><li><span class="Italics">General disorders and administration site condition:</span> Fever, hemorrhage of operative wound&nbsp;</li><li><span class="Italics">Hepatobiliary disorders:</span> Acute liver failure, hepatitis (non-infectious), abnormal liver function test&nbsp;&nbsp;</li><li><span class="Italics">Immune system disorders:</span> Hypersensitivity reactions, anaphylactoid reactions, serum sickness&nbsp;</li><li><span class="Italics">Musculoskeletal, connective tissue and bone disorders: </span>Musculoskeletal bleeding, myalgia, arthralgia, arthritis&nbsp;</li><li><span class="Italics">Nervous system disorders:</span> Taste disorders, fatal intracranial bleeding, headache&nbsp;&nbsp;&nbsp;</li><li><span class="Italics">Psychiatric disorders:</span> Confusion, hallucinations&nbsp;&nbsp;</li><li><span class="Italics">Respiratory, thoracic and mediastinal disorders:</span> Bronchospasm, interstitial pneumonitis, respiratory tract bleeding&nbsp;&nbsp;</li><li><span class="Italics">Renal and urinary disorders:&nbsp;</span>Increased creatinine levels&nbsp;</li><li><span class="Italics">Skin and subcutaneous tissue disorders:</span>&nbsp; Maculopapular or erythematous rash, urticaria, bullous dermatitis, eczema, toxic epidermal necrolysis, Stevens-Johnson syndrome, angioedema, erythema multiforme, skin bleeding, lichen planus, generalized pruritus&nbsp;&nbsp;</li><li><span class="Italics">Vascular disorders:</span> Vasculitis, hypotension </li></ul></div></div><div class="Section" data-sectionCode="34073-7"><a name="Section_7"></a><a name="section-7"></a><p></p><h1>7 DRUG INTERACTIONS</h1><div class="Section" data-sectionCode="42229-5"><a name="Section_7.1"></a><a name="section-7.1"></a><p></p><h2>7.1 CYP2C19 Inhibitors</h2><br><p class="First">Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of certain drugs that inhibit the activity of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a> and <a href="#Section_2.4">Dosage and Administration (2.4)</a>]</span>.<br><span class="Italics"><span class="Underline"><br>Proton Pump Inhibitors (PPI)</span><br>&nbsp;<br></span>Avoid concomitant use of clopidogrel bisulfate with omeprazole or esomeprazole. In clinical studies, omeprazole was shown to reduce the antiplatelet activity of clopidogrel bisulfate when given concomitantly or 12 hours apart. A higher dose regimen of clopidogrel concomitantly administered with omeprazole increases antiplatelet response; an appropriate dose regimen has not been established. A similar reduction in antiplatelet activity was observed with esomeprazole when given concomitantly with clopidogrel bisulfate. Consider using another acid-reducing agent with minimal or no CYP2C19 inhibitory effect on the formation of clopidogrel active metabolite. Dexlansoprazole, lansoprazole and pantoprazole had less effect on the antiplatelet activity of clopidogrel bisulfate than did omeprazole or esomeprazole <span class="Italics">[see <a href="#Section_2.4">Dosage and Administration (2.4)</a>, <a href="#Section_5.1">Warnings and Precautions (5.1)</a> and <a href="#Section_12.3">Clinical Pharmacology  (12.3)</a></span><span class="Italics">].</span></p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_7.2"></a><a name="section-7.2"></a><p></p><h2>7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</h2><br><p class="First">Coadministration of clopidogrel bisulfate and NSAIDs increases the risk of gastrointestinal bleeding.</p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_7.3"></a><a name="section-7.3"></a><p></p><h2>7.3 Warfarin (CYP2C9 Substrates)</h2><br><p class="First">Although the administration of clopidogrel 75 mg per day did not modify the pharmacokinetics of S-warfarin (a CYP2C9 substrate) or INR in patients receiving long-term warfarin therapy, coadministration of clopidogrel bisulfate with warfarin increases the risk of bleeding because of independent effects on hemostasis.<br><br>However, at high concentrations <span class="Italics">in vitr</span>o, clopidogrel inhibits CYP2C9.</p></div></div><div class="Section" data-sectionCode="43684-0"><a name="Section_8"></a><a name="section-8"></a><p></p><h1>8 USE IN SPECIFIC POPULATIONS</h1><div class="Section" data-sectionCode="42228-7"><a name="Section_8.1"></a><a name="section-8.1"></a><p></p><h2>8.1 Pregnancy</h2><br><p class="First"><span class="Italics"><span class="Underline">Pregnancy Category B</span><br>&nbsp;<br></span>Reproduction studies performed in rats and rabbits at doses up to 500 and 300 mg/kg/day, respectively (65 and 78 times the recommended daily human dose, respectively, on a mg/m<span class="Sup">2</span>basis), revealed no evidence of impaired fertility or fetotoxicity due to clopidogrel. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of a human response, clopidogrel bisulfate should be used during pregnancy only if clearly needed.</p></div><div class="Section" data-sectionCode="34080-2"><a name="Section_8.3"></a><a name="section-8.2"></a><p></p><h2>8.3 Nursing Mothers</h2><br><p class="First">Studies in rats have shown that clopidogrel and/or its metabolites are excreted in the milk. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from clopidogrel, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p></div><div class="Section" data-sectionCode="34081-0"><a name="Section_8.4"></a><a name="section-8.3"></a><p></p><h2>8.4 Pediatric Use</h2><br><p class="First" style="border-left:1px solid;">Safety&nbsp;<span class="XmChange"><span class="XmChange"><span class="XmChange">and</span></span></span> effectiveness in&nbsp;pediatric populations have not been established.&nbsp;<br><br>Additional information describing <span class="XmChange"><span class="XmChange"><span class="XmChange">a</span></span></span> clinical study in which efficacy was not demonstrated in neonates and infants is approved in the package insert for Bristol-Myers Squibb&rsquo;s clopidogrel tablets. However, due to Bristol-Myers Squibb&rsquo;s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</p></div><div class="Section" data-sectionCode="34082-8"><a name="Section_8.5"></a><a name="section-8.4"></a><p></p><h2>8.5 Geriatric Use</h2><br><p class="First">Of the total number of subjects in the CAPRIE and CURE controlled clinical studies, approximately 50% of patients treated with clopidogrel bisulfate were 65 years of age and older, and 15% were 75 years and older. In COMMIT, approximately 58% of the patients treated with clopidogrel bisulfate were 60 years and older, 26% of whom were 70 years and older.&nbsp;<br><br>The observed risk of bleeding events with clopidogrel bisulfate plus aspirin versus placebo plus aspirin by age category is provided in Table 1 and Table 2 for the CURE and COMMIT trials, respectively <span class="Italics">[see <a href="#Section_6.1">Adverse Reactions (6.1)</a>]</span>. No dosage adjustment is necessary in elderly patients. </p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_8.6"></a><a name="section-8.5"></a><p></p><h2>8.6 Renal Impairment</h2><br><p class="First">Experience is limited in patients with severe and moderate renal impairment <span class="Italics">[see <a href="#Section_12.2">Clinical Pharmacology (12.2)</a>].</span></p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_8.7"></a><a name="section-8.6"></a><p></p><h2>8.7 Hepatic Impairment</h2><br><p class="First">No dosage adjustment is necessary in patients with hepatic impairment <span class="Italics">[see <a href="#Section_12.2">Clinical Pharmacology (12.2)</a>]</span>. </p></div></div><div class="Section" data-sectionCode="34088-5"><a name="Section_10"></a><a name="section-9"></a><p></p><h1>10 OVERDOSAGE</h1><br><p class="First">Platelet inhibition by clopidogrel bisulfate is irreversible and will last for the life of the platelet. Overdose following clopidogrel administration may result in bleeding complications. A single oral dose of clopidogrel at 1500 or 2000 mg/kg was lethal to mice and to rats and at 3000 mg/kg to baboons. Symptoms of acute toxicity were vomiting, prostration, difficult breathing, and gastrointestinal hemorrhage in animals.<br><br>Based on biological plausibility, platelet transfusion may restore clotting ability. </p></div><div class="Section" data-sectionCode="34089-3"><a name="Section_11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><br><p class="First">Clopidogrel bisulfate is a thienopyridine class inhibitor of P2Y<span class="Sub">12</span> ADP platelet receptors. Chemically it is methyl (+)-(<span class="Italics">S</span>)-â›™-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4<span class="Italics">H</span>)-&shy;acetate sulfate (1:1). The molecular formula of clopidogrel bisulfate is C<span class="Sub">16</span>H<span class="Sub">16</span>ClNO<span class="Sub">2</span>S&bull;H<span class="Sub">2</span>SO<span class="Sub">4</span> and its molecular weight is 419.9.<br><br>The structural formula is as follows: </p><br><div class="Figure"><img src="/dailymed/archives/image.cfm?archiveid=107884&type=img&name=clopidogrel-str.jpg" alt="Clopidogrel Structure"></div><br><br><p>Clopidogrel bisulfate USP is a white to off-white powder. It is practically insoluble in water at neutral pH but freely soluble at pH 1. It also dissolves freely in methanol, dissolves sparingly in methylene chloride, and is practically insoluble in ethyl ether. It has a specific optical rotation of about +56&deg;.&nbsp;<br><br>Clopidogrel tablets, USP for oral administration are provided as pink colored, round, biconvex, beveled edge, debossed, film-coated tablets containing 97.875 mg of clopidogrel bisulfate which is the molar equivalent of 75 mg of clopidogrel base.<br><br>Each film-coated tablet contains crospovidone, hydrogenated castor oil, hydroxypropyl cellulose low substituted, hypromellose 15cP, iron oxide red, lactose monohydrate, mannitol, microcrystalline cellulose, polyethylene glycol 6000, titanium dioxide, and triacetin as inactive ingredients.</p></div><div class="Section" data-sectionCode="34090-1"><a name="Section_12"></a><a name="section-11"></a><p></p><h1>12 CLINICAL PHARMACOLOGY</h1><div class="Section" data-sectionCode="43679-0"><a name="Section_12.1"></a><a name="section-11.1"></a><p></p><h2>12.1 Mechanism of Action</h2><br><p class="First">Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y<span class="Sub">12</span> class of ADP receptors on platelets. </p></div><div class="Section" data-sectionCode="43681-6"><a name="Section_12.2"></a><a name="section-11.2"></a><p></p><h2>12.2 Pharmacodynamics</h2><br><p class="First">Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y<span class="Sub">12</span> receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.&nbsp;This action is irreversible. Consequently, platelets exposed to clopidogrel&rsquo;s active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).&nbsp; Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.<br><br>Dose-dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses of clopidogrel bisulfate. Repeated doses of 75 mg clopidogrel bisulfate per day inhibit ADP-induced platelet aggregation on the first day, and inhibition reaches steady state between Day 3 and Day 7. At steady state, the average inhibition level observed with a dose of 75 mg clopidogrel bisulfate per day was between 40% and 60%. Platelet aggregation and bleeding time gradually return to baseline values after treatment is discontinued, generally in about 5 days.<span class="Italics"><br><br><span class="Underline">Geriatric Patients</span><br></span>&nbsp;<br>Elderly (&ge;75 years) and young healthy subjects had similar effects on platelet aggregation.<span class="Italics"><br><br><span class="Underline">Renally-Impaired Patients</span><br></span>&nbsp;<br>After repeated doses of 75 mg clopidogrel bisulfate per day, patients with severe renal impairment (creatinine clearance from 5 to 15 mL/min) and moderate renal impairment (creatinine clearance from 30 to 60 mL/min) showed low (25%) inhibition of ADP-induced platelet aggregation.<span class="Italics"><br><br><span class="Underline">Hepatically-Impaired Patients</span><br></span>&nbsp;<br>After repeated doses of 75 mg clopidogrel bisulfate per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.<br><span class="Italics"><br><span class="Underline">Gender</span><br></span>&nbsp;<br>In a small study comparing men and women, less inhibition of ADP-induced platelet aggregation was observed in women.</p></div><div class="Section" data-sectionCode="43682-4"><a name="Section_12.3"></a><a name="section-11.3"></a><p></p><h2>12.3 Pharmacokinetics</h2><br><p class="First">Clopidogrel is a prodrug and is metabolized to a pharmacologically active metabolite and inactive metabolites.</p><span class="Italics"></span><br><br><p><span class="Underline">Absorption</span><br><br><br>After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed. Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.</p><span class="Italics"></span><br><br><p><span class="Underline">Effect of Food</span><br><br>&nbsp; <br>Clopidogrel bisulfate can be administered with or without food. In a study in healthy male subjects when clopidogrel bisulfate 75 mg per day was given with a standard breakfast, mean inhibition of ADP-induced platelet aggregation was reduced by less than 9%. The active metabolite AUC<span class="Sub">0-24</span> was unchanged in the presence of food, while there was a 57% decrease in active metabolite C<span class="Sub">max</span>. Similar results were observed when a clopidogrel bisulfate 300 mg loading dose was administered with a high-fat breakfast.<span class="Italics"><br><br><span class="Underline">Metabolism</span><br><br></span>&nbsp;<br>Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes. Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite. Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel. This metabolic pathway is mediated by CYP2C19, CYP3A, CYP2B6 and CYP1A2. The active thiol metabolite binds rapidly and irreversibly to platelet receptors, thus inhibiting platelet aggregation for the lifespan of the platelet.<br><br>The C<span class="Sub">max</span> of the active metabolite is twice as high following a single 300 mg clopidogrel loading dose as it is after four days of 75 mg maintenance dose. C<span class="Sub">max</span> occurs approximately 30 to 60 minutes after dosing. In the 75 to 300 mg dose range, the pharmacokinetics of the active metabolite deviates from dose proportionality: increasing the dose by a factor of four results in 2- and 2.7-fold increases in C<span class="Sub">max</span> and AUC, respectively.<br><span class="Italics"><br><span class="Underline">Elimination</span><br></span>&nbsp;<br>Following an oral dose of <span class="Sup">14</span>C-labeled clopidogrel in humans, approximately 50% of total radioactivity was excreted in urine and approximately 46% in feces over the 5 days post-dosing. After a single, oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours.&nbsp; The half-life of the active metabolite is about 30 minutes.<span class="Italics"><br><br>Drug Interactions<br>&nbsp;<br><br></span>Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of certain inhibitors of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition.<br><br><span class="Italics">Proton Pump Inhibitors (PPI) </span><br><br><br>The effect of proton pump inhibitors (PPI) on the systemic exposure to the clopidogrel active metabolite following multiple doses of clopidogrel bisulfate 75 mg evaluated in dedicated drug interaction studies is presented in Figure 1.</p><br><div class="Figure"><img src="/dailymed/archives/image.cfm?archiveid=107884&type=img&name=clopidogrel-fig1.jpg" alt="Figure 1: Exposure to Clopidogrel Active Metabolite Following Multiple Doses of Clopidogrel Bisulfate 75 mg Alone or with Proton Pump Inhibitors (PPIs)"></div><br><p>Pharmacodynamic and pharmacokinetic parameters measured in these studies showed that the interaction was highest with omeprazole and least with dexlansoprazole.</p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_12.4"></a><a name="section-11.4"></a><p></p><h2>12.5 Pharmacogenomics</h2><br><p class="First">CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite. Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by <span class="Italics">ex vivo </span>platelet aggregation assays, differ according to CYP2C19 genotype. Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel&rsquo;s active metabolite.<br><br>The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. Tests are available to determine a patient&rsquo;s CYP2C19 genotype.<br><br>A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metabolizer groups, evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg per day and 600 mg followed by 150 mg per day, each for a total of 5 days. Decreased active metabolite exposure and diminished inhibition of platelet aggregation were observed in the poor metabolizers as compared to the other groups. When poor metabolizers received the 600 mg/150 mg regimen, active metabolite exposure and antiplatelet response were greater than with the 300 mg/75 mg regimen (see Table 3). An appropriate dose regimen for this patient population has not been established in clinical outcome trials.</p><br><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><caption><span>Table 3: Active Metabolite Pharmacokinetics and Antiplatelet Responses by CYP2C19 Metabolizer Status 			</span></caption><thead><tr class="First Last"><th class="Lrule Rrule Toprule">&nbsp;</th><th class="Lrule Rrule Toprule" align="center">Dose</th><th class="Lrule Rrule Toprule" align="center">Ultrarapid<br>(n=10)</th><th class="Lrule Rrule Toprule" align="center">Extensive<br>(n=10)</th><th class="Lrule Rrule Toprule" align="center">Intermediate<br>(n=10)</th><th class="Lrule Rrule Toprule" align="center">Poor<br>(n=10)</th></tr></thead><tfoot><tr class="First Last"><td colspan="6">Values are mean (SD) <br>* Inhibition of platelet aggregation with 5 mcM ADP; larger value indicates greater platelet inhibition.<br><span class="Sup">&dagger;</span> Vasodilator-stimulated phosphoprotein &ndash; platelet reactivity index; smaller value indicates greater platelet inhibition.<br></td></tr></tfoot><tbody><tr class="Botrule First"><td class="Lrule Rrule" rowspan="4" valign="top">&nbsp;&nbsp;&nbsp;C<span class="Sub">max</span> (ng/mL)<br></td><td class="Rrule" align="center" valign="top">&nbsp;&nbsp;&nbsp;300 mg (24 h)<br></td><td class="Rrule" align="center" valign="top">24 (10)<br></td><td class="Rrule" align="center" valign="top">32 (21)<br></td><td class="Rrule" align="center" valign="top">23 (11)<br></td><td class="Rrule" align="center" valign="top">11 (4)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top">&nbsp;&nbsp;&nbsp;600 mg (24 h)<br></td><td class="Rrule" align="center" valign="top">36 (13)<br></td><td class="Rrule" align="center" valign="top">44 (27)<br></td><td class="Rrule" align="center" valign="top">39 (23)<br></td><td class="Rrule" align="center" valign="top">17 (6)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top">&nbsp;&nbsp;&nbsp;75 mg (Day 5)<br></td><td class="Rrule" align="center" valign="top">12 (6)<br></td><td class="Rrule" align="center" valign="top">13 (7)<br></td><td class="Rrule" align="center" valign="top">12 (5)<br></td><td class="Rrule" align="center" valign="top">4 (1)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top">&nbsp;&nbsp;&nbsp;150 mg (Day 5)<br></td><td class="Rrule" align="center" valign="top">16 (9)<br></td><td class="Rrule" align="center" valign="top">19 (5)<br></td><td class="Rrule" align="center" valign="top">18 (7)<br></td><td class="Rrule" align="center" valign="top">7 (2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" rowspan="4" valign="top">&nbsp;&nbsp;&nbsp;IPA (%)*<br></td><td class="Rrule" align="center" valign="top">&nbsp;&nbsp;&nbsp;300 mg (24 h)<br></td><td class="Rrule" align="center" valign="top">40 (21)<br></td><td class="Rrule" align="center" valign="top">39 (28)<br></td><td class="Rrule" align="center" valign="top">37 (21)<br></td><td class="Rrule" align="center" valign="top">24 (26)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top">&nbsp;&nbsp;&nbsp;600 mg (24 h)<br></td><td class="Rrule" align="center" valign="top">51 (28)<br></td><td class="Rrule" align="center" valign="top">49 (23)<br></td><td class="Rrule" align="center" valign="top">56 (22)<br></td><td class="Rrule" align="center" valign="top">32 (25)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top">&nbsp;&nbsp;&nbsp;75 mg (Day 5)<br></td><td class="Rrule" align="center" valign="top">56 (13)<br></td><td class="Rrule" align="center" valign="top">58 (19)<br></td><td class="Rrule" align="center" valign="top">60 (18)<br></td><td class="Rrule" align="center" valign="top">37 (23)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top">&nbsp;&nbsp;&nbsp;150 mg (Day 5)<br></td><td class="Rrule" align="center" valign="top">68 (18)<br></td><td class="Rrule" align="center" valign="top">73 (9)<br></td><td class="Rrule" align="center" valign="top">74 (14)<br></td><td class="Rrule" align="center" valign="top">61 (14)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" rowspan="4" valign="top">&nbsp;&nbsp;&nbsp;VASP-PRI (%)<span class="Sup">&dagger;</span><br></td><td class="Rrule" align="center" valign="top">&nbsp;&nbsp;&nbsp;300 mg (24 h)<br></td><td class="Rrule" align="center" valign="top">73 (12)<br></td><td class="Rrule" align="center" valign="top">68 (16)<br></td><td class="Rrule" align="center" valign="top">78 (12)<br></td><td class="Rrule" align="center" valign="top">91 (12)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top">&nbsp;&nbsp;&nbsp;600 mg (24 h)<br></td><td class="Rrule" align="center" valign="top">51 (20)<br></td><td class="Rrule" align="center" valign="top">48 (20)<br></td><td class="Rrule" align="center" valign="top">56 (26)<br></td><td class="Rrule" align="center" valign="top">85 (14)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top">&nbsp;&nbsp;&nbsp;75 mg (Day 5)<br></td><td class="Rrule" align="center" valign="top">40 (9)<br></td><td class="Rrule" align="center" valign="top">39 (14)<br></td><td class="Rrule" align="center" valign="top">50 (16)<br></td><td class="Rrule" align="center" valign="top">83 (13)<br></td></tr><tr class="Last"><td class="Lrule Rrule" align="center" valign="top">&nbsp;&nbsp;&nbsp;150 mg (Day 5)<br></td><td class="Rrule" align="center" valign="top">20 (10)<br></td><td class="Rrule" align="center" valign="top">24 (10)<br></td><td class="Rrule" align="center" valign="top">29 (11)<br></td><td class="Rrule" align="center" valign="top">61 (18)<br></td></tr></tbody></table><p>Some published studies suggest that intermediate metabolizers have decreased active metabolite exposure and diminished antiplatelet effects.<br><br>The relationship between CYP2C19 genotype and clopidogrel bisulfate treatment outcome was evaluated in retrospective analyses of clopidogrel bisulfate-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.</p></div></div><div class="Section" data-sectionCode="43680-8"><a name="Section_13"></a><a name="section-12"></a><p></p><h1>13 NONCLINICAL TOXICOLOGY</h1><div class="Section" data-sectionCode="34083-6"><a name="Section_13.1"></a><a name="section-12.1"></a><p></p><h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><br><p class="First">There was no evidence of tumorigenicity when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats at dosages up to 77 mg/kg per day, which afforded plasma exposures &gt;25 times that in humans at the recommended daily dose of 75 mg.<br><br>Clopidogrel was not genotoxic in four <span class="Italics">in vitro </span>tests (Ames test, DNA-repair test in rat hepatocytes, gene mutation assay in Chinese hamster fibroblasts, and metaphase chromosome analysis of human lymphocytes) and in one <span class="Italics">in vivo </span>test (micronucleus test by oral route in mice).&nbsp;<br><br>Clopidogrel was found to have no effect on fertility of male and female rats at oral doses up to 400 mg/kg per day (52 times the recommended human dose on a mg/m<span class="Sup">2</span> basis). </p></div></div><div class="Section" data-sectionCode="34092-7"><a name="Section_14"></a><a name="section-13"></a><p></p><h1>14 CLINICAL STUDIES</h1><div class="Section" data-sectionCode="42229-5"><a name="Section_14.1"></a><a name="section-13.1"></a><p></p><h2>14.1 Acute Coronary Syndrome</h2><br><p class="First"><span class="Italics"><span class="Underline">CURE</span></span><br><br>The CURE study included 12,562 patients with ACS without ST-elevation (UA or NSTEMI) and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischemia. Patients were required to have either ECG changes compatible with new ischemia (without ST-elevation) or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal. The patient population was largely Caucasian (82%) and included 38% women, and 52% patients &ge;65 years of age.<br><br><br>Patients were randomized to receive clopidogrel bisulfate (300 mg loading dose followed by 75 mg once daily) or placebo, and were treated for up to one year. Patients also received aspirin (75 to 325 mg once daily) and other standard therapies such as heparin. The use of GPIIb/IIIa inhibitors was not permitted for three days prior to randomization.<br><br>The number of patients experiencing the primary outcome (CV death, MI, or stroke) was 582 (9.3%) in the clopidogrel bisulfate-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10% to 28%; p &lt; 0.001) for the clopidogrel bisulfate-treated group (see Table 4). </p><br><table border="0" cellpadding="0" cellspacing="0" width="603"><caption><span>Table 4: Outcome Events in the CURE Primary Analysis 			</span></caption><thead><tr class="First Last"><th class="Lrule Rrule Toprule" align="center">Outcome</th><th class="Lrule Rrule Toprule" align="center">Clopidogrel Bisulfate<br>(+ aspirin)*<br>(n=6259)</th><th class="Lrule Rrule Toprule" align="center">Placebo<br>(+ aspirin)*<br>(n=6303)</th><th class="Lrule Rrule Toprule" align="center">Relative Risk<br>Reduction (%)<br>(95% CI)</th></tr></thead><tfoot><tr class="First Last"><td colspan="4">* Other standard therapies were used as appropriate. <br><span class="Sup">&dagger;</span> The individual components do not represent a breakdown of the primary and co-primary outcomes, but rather the total number of subjects experiencing an event during the course of the study. <br></td></tr></tfoot><tbody><tr class="Botrule First"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;Primary outcome<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Cardiovascular death, MI, stroke) <br></td><td class="Rrule" align="center" valign="top">582<br>(9.3%)<br></td><td class="Rrule" align="center" valign="top">719<br>(11.4%)<br></td><td class="Rrule" align="center" valign="top">20%<br>(10.3, 27.9)<br>p &lt; 0.001<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;All Individual Outcome Events:<span class="Sup">&dagger;</span><br></td><td class="Rrule" align="center" valign="top"></td><td class="Rrule" align="center" valign="top"></td><td class="Rrule" align="center" valign="top"></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CV death <br></td><td class="Rrule" align="center" valign="top">318<br>(5.1%)<br></td><td class="Rrule" align="center" valign="top">345<br>(5.5%)<br></td><td class="Rrule" align="center" valign="top">7%<br>(-7.7, 20.6)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MI <br></td><td class="Rrule" align="center" valign="top">324<br>(5.2%)<br></td><td class="Rrule" align="center" valign="top">419<br>(6.6%)<br></td><td class="Rrule" align="center" valign="top">23%<br>(11, 33.4)<br></td></tr><tr class="Last"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stroke <br></td><td class="Rrule" align="center" valign="top">75<br>(1.2%)<br></td><td class="Rrule" align="center" valign="top">87<br>(1.4%)<br></td><td class="Rrule" align="center" valign="top">14%<br>(-17.7, 36.6)<br></td></tr></tbody></table><p>Most of the benefit of clopidogrel bisulfate occurred in the first two months, but the difference from placebo was maintained throughout the course of the trial (up to 12 months) (see Figure 2).</p><br><div class="Figure"><img src="/dailymed/archives/image.cfm?archiveid=107884&type=img&name=clopidogrel-fig2.jpg" alt="Figure 2: Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study"></div><p>In CURE, the use of clopidogrel bisulfate was associated with a lower incidence of CV death, MI or stroke in patient populations with different characteristics, as shown in Figure 3. The benefits associated with clopidogrel bisulfate were independent of the use of other acute and long-term cardiovascular therapies, including heparin/LMWH, intravenous glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors, lipid-lowering drugs, beta-blockers, and ACE-inhibitors. The efficacy of clopidogrel bisulfate was observed independently of the dose of aspirin (75 to 325 mg once daily). The use of oral anticoagulants, non-study antiplatelet drugs, and chronic NSAIDs was not allowed in CURE. </p><br><br><div class="Figure"><img src="/dailymed/archives/image.cfm?archiveid=107884&type=img&name=clopidogrel-fig3.jpg" alt="Figure 3: Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study"></div><p>The use of clopidogrel bisulfate in CURE was associated with a decrease in the use of thrombolytic therapy (71 patients [1.1%] in the clopidogrel bisulfate group, 126 patients [2%] in the placebo group; relative risk reduction of 43%), and GPIIb/IIIa inhibitors (369 patients [5.9%] in the clopidogrel bisulfate group, 454 patients [7.2%] in the placebo group, relative risk reduction of 18%). The use of clopidogrel bisulfate in CURE did not affect the number of patients treated with CABG or PCI (with or without stenting), (2253 patients [36%] in the clopidogrel bisulfate group, 2324 patients [36.9%] in the placebo group; relative risk reduction of 4%).<br><br><span class="Italics"><br><span class="Underline">COMMIT</span></span><br><br>In patients with STEMI, the safety and efficacy of clopidogrel bisulfate were evaluated in the randomized, placebo-controlled, double-blind study, COMMIT. COMMIT included 45,852 patients presenting within 24 hours of the onset of the symptoms of myocardial infarction with supporting ECG abnormalities (<span class="Italics">i.e.</span>, ST-elevation, ST-depression or left bundle-branch block). Patients were randomized to receive clopidogrel bisulfate (75 mg once daily) or placebo, in combination with aspirin (162 mg per day), for 28 days or until hospital discharge, whichever came first.<br><br>The primary endpoints were death from any cause and the first occurrence of re-infarction, stroke or death.<br><br>The patient population included 28% women, 58% age &ge; 60 years (26% age &ge; 70 years), 55% patients who received thrombolytics, 68% who received ACE-inhibitors, and only 3% who underwent PCI.<br><br>As shown in Table&nbsp;5 and Figure&nbsp;4 and&nbsp;Figure&nbsp;5 below, clopidogrel bisulfate significantly reduced the relative risk of death from any cause by 7% (p=0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p=0.002).&nbsp;&nbsp;</p><br><table border="0" cellpadding="0" cellspacing="0" width="624"><caption><span>Table 5: Outcome Events in the COMMIT Analysis 			</span></caption><thead><tr class="First Last"><th class="Lrule Rrule Toprule" align="center">Event</th><th class="Lrule Rrule Toprule" align="center">Clopidogrel Bisulfate<br>(+ aspirin)<br>(N=22961)</th><th class="Lrule Rrule Toprule" align="center">Placebo<br>(+ aspirin)<br>(N=22891)</th><th class="Lrule Rrule Toprule" align="center">Odds ratio<br>(95% CI)</th><th class="Lrule Rrule Toprule" align="center">p-value</th></tr></thead><tfoot><tr class="First Last"><td colspan="5">* The difference between the composite endpoint and the sum of death+non-fatal MI+non-fatal stroke indicates that 9 patients (2 clopidogrel and 7 placebo) suffered both a non-fatal stroke and a non-fatal MI. <br>** Non-fatal MI and non-fatal stroke exclude patients who died (of any cause). <br></td></tr></tfoot><tbody><tr class="Botrule First"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">Composite endpoint: Death,</span><br><span class="Bold">MI, or Stroke*</span><br></td><td class="Rrule" align="center" valign="top">2121 (9.2%)<br></td><td class="Rrule" align="center" valign="top">2310 (10.1%)<br></td><td class="Rrule" align="center" valign="top">0.91 (0.86, 0.97)<br></td><td class="Rrule" align="center" valign="top">0.002<br></td></tr><tr class="Last"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">Death</span><br>Non-fatal MI**<br>Non-fatal Stroke**<br></td><td class="Rrule" align="center" valign="top">1726 (7.5%)<br>270 (1.2%)<br>127 (0.6%)<br></td><td class="Rrule" align="center" valign="top">1845 (8.1%)<br>330 (1.4%)<br>142 (0.6%)<br></td><td class="Rrule" align="center" valign="top">0.93 (0.87, 0.99)<br>0.81 (0.69, 0.95)<br>0.89 (0.7, 1.13)<br></td><td class="Rrule" align="center" valign="top">0.029<br>0.011<br>0.33<br></td></tr></tbody></table><br><div class="Figure"><img src="/dailymed/archives/image.cfm?archiveid=107884&type=img&name=clopidogrel-fig4.jpg" alt="Figure 4: Cumulative Event Rates for Death in the COMMIT Study*"></div><br><div class="Figure"><img src="/dailymed/archives/image.cfm?archiveid=107884&type=img&name=clopidogrel-fig5.jpg" alt="Figure 5: Cumulative Event Rates for the Combined Endpoint Re-Infarction, Stroke or Death in the COMMIT Study*"></div><p>The effect of clopidogrel bisulfate did not differ significantly in various pre-specified subgroups as shown in Figure 6. The effect was also similar in non-prespecified subgroups including those based on infarct location, Killip class or prior MI history (see Figure 7). Such subgroup analyses should be interpreted cautiously. </p><br><br><div class="Figure"><img src="/dailymed/archives/image.cfm?archiveid=107884&type=img&name=clopidogrel-fig6.jpg" alt="Figure 6: Effects of Adding Clopidogrel Bisulfate to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study"></div><p>* Three similar-sized prognostic index groups were based on absolute risk of primary composite outcome for each patient calculated from baseline prognostic variables (excluding allocated treatments) with a Cox regression model.</p><br><div class="Figure"><img src="/dailymed/archives/image.cfm?archiveid=107884&type=img&name=clopidogrel-fig7.jpg" alt="Figure 7: Effects of Adding Clopidogrel Bisulfate to Aspirin in the Non-Prespecified Subgroups in the COMMIT Study"></div></div><div class="Section" data-sectionCode="42229-5"><a name="Section_14.2"></a><a name="section-13.2"></a><p></p><h2>14.2 Recent Myocardial Infarction, Recent Stroke, or Established Peripheral Arterial Disease</h2><br><p class="First"><span class="Italics"><span class="Underline">CAPRIE</span></span><br><br>The CAPRIE trial was a 19,185-patient, 304-center, international, randomized, double-blind, parallel-group study comparing clopidogrel bisulfate (75 mg daily) to aspirin (325 mg daily). The patients randomized had: 1) recent histories of myocardial infarction (within 35 days); 2) recent histories of ischemic stroke (within 6 months) with at least a week of residual neurological signs; or 3) established peripheral arterial disease. Patients received randomized treatment for an average of 1.6 years (maximum of 3 years).<br><br>The trial&rsquo;s primary outcome was the time to first occurrence of new ischemic stroke (fatal or not), new myocardial infarction (fatal or not), or other vascular death. Deaths not easily attributable to nonvascular causes were all classified as vascular.</p><br><br><table border="0" cellpadding="0" cellspacing="0" width="624"><caption><span>Table 6: Outcome Events in the CAPRIE Primary Analysis 			</span></caption><thead><tr class="First Last"><th class="Lrule Rrule Toprule" align="center">Patients</th><th class="Lrule Rrule Toprule" align="center">Clopidogrel Bisulfate<br>n=9599</th><th class="Lrule Rrule Toprule" align="center">Aspirin<br>n=9586</th></tr></thead><tbody><tr class="Botrule First"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;Ischemic stroke (fatal or not) <br></td><td class="Rrule" align="center" valign="top">438 (4.6%)<br></td><td class="Rrule" align="center" valign="top">461 (4.8%)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;MI (fatal or not) <br></td><td class="Rrule" align="center" valign="top">275 (2.9%)<br></td><td class="Rrule" align="center" valign="top">333 (3.5%)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;Other vascular death <br></td><td class="Rrule" align="center" valign="top">226 (2.4%)<br></td><td class="Rrule" align="center" valign="top">226 (2.4%)<br></td></tr><tr class="Last"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;Total <br></td><td class="Rrule" align="center" valign="top">939 (9.8%)<br></td><td class="Rrule" align="center" valign="top">1020 (10.6%)<br></td></tr></tbody></table><p>As shown in Table 6, clopidogrel bisulfate was associated with a lower incidence of outcome events, primarily MI. The overall relative risk reduction (9.8% vs. 10.6%) was 8.7%, p=0.045. Similar results were obtained when all-cause mortality and all-cause strokes were counted instead of vascular mortality and ischemic strokes (risk reduction 6.9%). In patients who survived an on-study stroke or myocardial infarction, the incidence of subsequent events was lower in the clopidogrel bisulfate group.<br><br>The curves showing the overall event rate are shown in Figure 8. The event curves separated early and continued to diverge over the 3-year follow-up period. </p><br><div class="Figure"><img src="/dailymed/archives/image.cfm?archiveid=107884&type=img&name=clopidogrel-fig8.jpg" alt="Figure 8: Fatal or Non-Fatal Vascular Events in the CAPRIE Study"></div><p>The statistical significance favoring clopidogrel bisulfate over aspirin was marginal (p=0.045). However, because aspirin is itself effective in reducing cardiovascular events in patients with recent myocardial infarction or stroke, the effect of clopidogrel bisulfate is substantial.<br><br>The CAPRIE trial included a population that was randomized on the basis of 3 entry criteria. The efficacy of clopidogrel bisulfate relative to aspirin was heterogeneous across these randomized subgroups (p=0.043). It is not clear whether this difference is real or a chance occurrence. Although the CAPRIE trial was not designed to evaluate the relative benefit of clopidogrel bisulfate over aspirin in the individual patient subgroups, the benefit appeared to be strongest in patients who were enrolled because of peripheral vascular disease (especially those who also had a history of myocardial infarction) and weaker in stroke patients. In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel bisulfate was not numerically superior to aspirin.</p></div><div class="Section" data-sectionCode="42229-5"><a name="Section_14.3"></a><a name="section-13.3"></a><p></p><h2>14.3 Lack of Established Benefit of Clopidogrel Bisulfate plus Aspirin in Patients with Multiple Risk Factors or Established Vascular Disease</h2><br><p class="First"><span class="Italics"><span class="Underline">CHARISMA </span><br>&nbsp;<br></span>The CHARISMA trial was a 15,603 subject, randomized, double-blind, parallel group study comparing clopidogrel bisulfate (75 mg daily) to placebo for prevention of ischemic events in patients with vascular disease or multiple risk factors for atherosclerosis. All subjects were treated with aspirin 75 to 162 mg daily. The mean duration of treatment was 23 months. The study failed to demonstrate a reduction in the occurrence of the primary endpoint, a composite of CV death, MI, or stroke. A total of 534 (6.9%) patients in the clopidogrel bisulfate group versus 573 (7.4%) patients in the placebo group experienced a primary outcome event (p=0.22). Bleeding of all severities was more common in the subjects randomized to clopidogrel bisulfate.</p></div></div><div class="Section" data-sectionCode="34069-5"><a name="Section_16"></a><a name="section-14"></a><p></p><h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1><br><p class="First"><span class="Bold">Clopidogrel Tablets USP, 75 mg </span>are pink colored, round, biconvex, beveled edge, film-coated tablets debossed with &lsquo;E&rsquo; on one side and &lsquo;34&rsquo; on the other side.<br><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bottles of 90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NDC 59762-6700-2<br><br><span class="Bold">Store at 20&deg; to 25&deg;C (68&deg; to 77&deg;F); excursions permitted to 15&deg; to 30&deg;C (59&deg; to 86&deg;F) [see USP Controlled Room Temperature]. Protect from moisture.&nbsp;</span><br><br><span class="Bold">Preserve in well-closed containers.</span></p></div><div class="Section" data-sectionCode="34076-0"><a name="Section_17"></a><a name="section-15"></a><p></p><h1>17 PATIENT COUNSELING INFORMATION</h1><br><p class="First"><span class="Italics">[See <a href="#Section_21">Medication Guide (17.6)</a>]</span></p><div class="Section" data-sectionCode="42229-5"><a name="Section_17.1"></a><a name="section-15.1"></a><p></p><h2>17.1 Benefits and Risks</h2><br><ul class="Disc"><li>Summarize the effectiveness features and potential side effects of clopidogrel bisulfate. </li><li>Tell patients to take clopidogrel bisulfate exactly as prescribed. </li><li>Remind patients not to discontinue clopidogrel bisulfate without first discussing it with the physician who prescribed clopidogrel bisulfate.</li></ul></div><div class="Section" data-sectionCode="42229-5"><a name="Section_17.2"></a><a name="section-15.2"></a><p></p><h2>17.2 Bleeding</h2><br><p class="First">Inform patients that they:</p><br><ul class="Disc"><li>will bruise and bleed more easily. </li><li>will take longer than usual to stop bleeding. </li><li>should report any unanticipated, prolonged, or excessive bleeding, or blood in their stool or urine. </li></ul></div><div class="Section" data-sectionCode="42229-5"><a name="Section_17.3"></a><a name="section-15.3"></a><p></p><h2>17.3 Other Signs and Symptoms Requiring Medical Attention</h2><br><ul class="Disc"><li>Inform patients that TTP is a rare but serious condition that has been reported with clopidogrel bisulfate and other drugs in this class of drugs.</li><li>Instruct patients to get prompt medical attention if they experience any of the following symptoms that cannot otherwise be explained: fever, weakness, extreme skin paleness, purple skin patches, yellowing of the skin or eyes, or neurological changes.</li></ul></div><div class="Section" data-sectionCode="42229-5"><a name="Section_17.4"></a><a name="section-15.4"></a><p></p><h2>17.4 Invasive Procedures</h2><br><p class="First">Instruct patients to:</p><br><ul class="Disc"><li>inform physicians and dentists that they are taking clopidogrel bisulfate before any invasive procedure is scheduled. </li><li>tell the doctor performing the invasive procedure to talk to the prescribing health care professional before stopping clopidogrel bisulfate.</li></ul></div><div class="Section" data-sectionCode="42229-5"><a name="Section_17.5"></a><a name="section-15.5"></a><p></p><h2>17.5 Concomitant Medications</h2><br><p class="First">Ask patients to list all prescription medications, over-the-counter medications, or dietary supplements they are taking or plan to take, including prescription or over-the-counter proton pump inhibitors (e.g., omeprazole), warfarin or NSAIDs <span class="Italics">[see <a href="#Section_5">Warnings and Precautions (5)</a>]</span>.</p></div></div><div class="Section" data-sectionCode="42231-1"><a name="Section_21"></a><a name="section-16"></a><p></p><h1>17.6 Medication Guide</h1><br><p class="First"><span class="Bold">Medication Guide</span><br><span class="Bold">Clopidogrel Tablets, USP&nbsp;</span><br><br>Read this Medication Guide before you start taking clopidogrel tablets and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.</p><span class="Bold"></span><br><br><p><span class="Bold">What&nbsp;is&nbsp;the&nbsp;most&nbsp;important&nbsp;information&nbsp;I&nbsp;should&nbsp;know&nbsp;about&nbsp;clopidogrel&nbsp;tablets?</span><br><br><span class="Bold">1.&nbsp;Clopidogrel&nbsp;tablets</span>&nbsp;<span class="Bold">may not&nbsp;work as&nbsp;well&nbsp;in&nbsp;people&nbsp;who:</span></p><br><br><ul class="Disc"><li><span class="Bold">have&nbsp;certain genetic factors&nbsp;that&nbsp;affect&nbsp;how&nbsp;the&nbsp;body breaks down clopidogrel tablets. </span>Your doctor may do genetic tests to make sure clopidogrel tablets are right for you.    </li><li><span class="Bold">take certain&nbsp;medicines,&nbsp;especially&nbsp;omeprazole&nbsp;(Prilosec<span class="Sup">&reg;</span>) or esomeprazole (Nexium<span class="Sup">&reg;</span>). </span>Your doctor may change the medicine you take for stomach acid problems while you take clopidogrel tablets.<br><span class="Bold"></span></li></ul><br><p><span class="Bold">2.&nbsp;Clopidogrel&nbsp;tablets</span>&nbsp;<span class="Bold">can&nbsp;cause&nbsp;bleeding&nbsp;which&nbsp;can&nbsp;be&nbsp;serious&nbsp;and&nbsp;can&nbsp;sometimes&nbsp;lead&nbsp;to&nbsp;death. </span>Clopidogrel tablets are a blood thinner medicine that lowers the chance of blood clots forming in your body. While you take clopidogrel tablets:</p><br><ul class="Disc"><li>you&nbsp;may&nbsp;bruise&nbsp;and&nbsp;bleed&nbsp;more&nbsp;easily</li><li>you&nbsp;are&nbsp;more&nbsp;likely&nbsp;to&nbsp;have&nbsp;nose&nbsp;bleeds</li><li>it&nbsp;will&nbsp;take&nbsp;longer&nbsp;for&nbsp;any&nbsp;bleeding&nbsp;to&nbsp;stop</li></ul><br><p>Call&nbsp;your&nbsp;doctor&nbsp;right&nbsp;away&nbsp;if&nbsp;you&nbsp;have any&nbsp;of&nbsp;these&nbsp;signs&nbsp;or&nbsp;symptoms&nbsp;of&nbsp;bleeding:</p><br><ul class="Disc"><li>unexpected&nbsp;bleeding&nbsp;or&nbsp;bleeding&nbsp;that&nbsp;lasts&nbsp;a&nbsp;long&nbsp;time</li><li>blood&nbsp;in&nbsp;your&nbsp;urine&nbsp;(pink,&nbsp;red&nbsp;or&nbsp;brown&nbsp;urine)</li><li>red&nbsp;or&nbsp;black&nbsp;stools&nbsp;(looks&nbsp;like&nbsp;tar)</li><li>bruises&nbsp;that&nbsp;happen&nbsp;without&nbsp;a&nbsp;known&nbsp;cause&nbsp;or&nbsp;get&nbsp;larger</li><li>cough&nbsp;up&nbsp;blood&nbsp;or&nbsp;blood&nbsp;clots</li><li>vomit&nbsp;blood&nbsp;or&nbsp;your&nbsp;vomit&nbsp;looks&nbsp;like&nbsp;coffee&nbsp;grounds</li></ul><br><p>Do not stop taking clopidogrel tablets without talking to the doctor who prescribes them for you. People who are treated with a stent, and stop taking clopidogrel tablets too soon, have a higher risk of getting a blood clot on the stent, having a heart attack, or dying. If you must stop clopidogrel tablets because of bleeding, your risk of a heart attack may be higher.<span class="Bold"><br><br>What&nbsp;are&nbsp;clopidogrel&nbsp;tablets?</span><br><br>Clopidogrel tablets are a prescription medicine used to treat people who have any of the following:</p><br><ul class="Disc"><li>chest&nbsp;pain&nbsp;due&nbsp;to&nbsp;heart&nbsp;problems</li><li>poor&nbsp;circulation&nbsp;in&nbsp;their&nbsp;legs&nbsp;(peripheral&nbsp;arterial&nbsp;disease)</li><li>a&nbsp;heart&nbsp;attack</li><li>a&nbsp;stroke</li></ul><br><p>Clopidogrel&nbsp;tablets are used alone or with aspirin to lower your chance of having another serious problem with your heart or blood vessels such as heart attack, stroke, or blood clot that can lead to death.<br><br>Platelets are blood cells that help your blood clot normally. Clopidogrel tablets help to prevent platelets from sticking together and forming a clot that can block an artery.<br><br>It&nbsp;is&nbsp;not&nbsp;known&nbsp;if&nbsp;clopidogrel&nbsp;tablets&nbsp;are&nbsp;safe&nbsp;and&nbsp;effective&nbsp;in&nbsp;children.<span class="Bold"><br><br>Who&nbsp;should&nbsp;not&nbsp;take&nbsp;clopidogrel&nbsp;tablets?</span><br><br>Do&nbsp;not&nbsp;take&nbsp;clopidogrel&nbsp;tablets if you:</p><br><ul class="Disc"><li>currently&nbsp;have&nbsp;a&nbsp;condition&nbsp;that&nbsp;causes&nbsp;bleeding,&nbsp;such&nbsp;as&nbsp;a&nbsp;stomach&nbsp;ulcer </li><li>are allergic to clopidogrel or other ingredients in clopidogrel tablets. See the end of this leaflet for a complete list of ingredients in clopidogrel tablets.</li></ul><p><span class="Bold"><br>What&nbsp;should&nbsp;I&nbsp;tell&nbsp;my&nbsp;doctor&nbsp;before&nbsp;taking&nbsp;clopidogrel&nbsp;tablets?</span><br><br>Before&nbsp;you&nbsp;take&nbsp;clopidogrel&nbsp;tablets,&nbsp;tell&nbsp;your&nbsp;doctor&nbsp;if&nbsp;you:</p><br><ul class="Disc"><li>have&nbsp;a&nbsp;history&nbsp;of&nbsp;bowel&nbsp;(gastrointestinal)&nbsp;or&nbsp;stomach&nbsp;ulcers</li><li>have a history of&nbsp;bleeding&nbsp;problems</li><li>plan&nbsp;to have&nbsp;surgery&nbsp;or&nbsp;a&nbsp;dental&nbsp;procedure. See <span class="Bold">&ldquo;How should I take clopidogrel tablets?</span>&rdquo;</li><li>are pregnant or plan to become pregnant. It is not known if clopidogrel tablets will harm your unborn baby</li><li>are breastfeeding&nbsp;or plan to breastfeed. It is not known if clopidogrel bisulfate passes into your breast milk. You and your doctor should decide if you will take clopidogrel tablets or breastfeed. You should not do both without talking to your doctor.</li></ul><br><p>Tell all of your doctors and your dentist that you are taking clopidogrel tablets. They should talk to the doctor who prescribed clopidogrel tablets for you before you have any surgery or invasive procedure.<span class="Bold"><br><br>Tell your doctor about all the medicines you take, </span>including prescription, non-prescription medicines, vitamins and herbal supplements.<br><br>Clopidogrel tablets may affect the way other medicines work, and other medicines may affect how clopidogrel tablets work. See <span class="Bold">&ldquo;What is the most important information I should know about clopidogrel tablets?&rdquo;<br>&nbsp;<br><br></span>Taking clopidogrel tablets with certain other medicines may increase your risk of bleeding. <span class="Bold">Especially tell your doctor if you take:</span></p><br><ul class="Disc"><li>aspirin, especially if you have had a stroke. Always talk to your doctor about whether you should take aspirin along with clopidogrel tablets to treat your condition.</li><li>Non-steroidal anti-inflammatory drugs (NSAIDs). Ask your doctor or pharmacist for a list of NSAID medicines if you are not sure.</li><li>warfarin&nbsp;(Coumadin<span class="Sup">&reg;</span>,&nbsp;Jantoven<span class="Sup">&reg;</span>)</li></ul><br><p>Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine.<span class="Bold"><br><br>How&nbsp;should&nbsp;I&nbsp;take&nbsp;clopidogrel tablets?</span></p><br><ul class="Disc"><li>Take&nbsp;clopidogrel&nbsp;tablets&nbsp;exactly&nbsp;as&nbsp;your&nbsp;doctor&nbsp;tells&nbsp;you.</li><li>Do not change your dose or stop taking clopidogrel tablets without talking to your doctor first. Stopping clopidogrel tablets may increase your risk of heart attack or stroke.</li><li>Take&nbsp;clopidogrel&nbsp;tablets&nbsp;with&nbsp;aspirin&nbsp;as&nbsp;instructed&nbsp;by&nbsp;your&nbsp;doctor.</li><li>You can&nbsp;take&nbsp;clopidogrel&nbsp;tablets&nbsp;with&nbsp;or&nbsp;without&nbsp;food.</li><li>If you miss a dose, take clopidogrel tablets as soon as you remember. If it is almost time for your next dose, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses of clopidogrel tablets at the same time unless your doctor tells you to.</li><li>If you take too much clopidogrel bisulfate, call your doctor or go to the nearest emergency room right away.</li><li>Talk with your doctor about stopping your clopidogrel tablets before you have surgery. Your doctor may tell you to stop taking clopidogrel tablets at least 5 days before you have surgery to avoid excessive bleeding during surgery.</li></ul><p><span class="Bold"><br>What&nbsp;are&nbsp;the&nbsp;possible&nbsp;side&nbsp;effects&nbsp;of&nbsp;clopidogrel&nbsp;tablets?</span><br><br><span class="Bold">Clopidogrel&nbsp;tablets</span>&nbsp;<span class="Bold">can&nbsp;cause&nbsp;serious&nbsp;side&nbsp;effects&nbsp;including:</span>&nbsp;</p><br><ul class="Disc"><li>See&nbsp;<span class="Bold">&ldquo;What is&nbsp;the&nbsp;most&nbsp;important&nbsp;information&nbsp;I&nbsp;should&nbsp;know&nbsp;about&nbsp;clopidogrel&nbsp;tablets?&rdquo;</span></li><li><span class="Bold">A blood clotting problem called Thrombotic Thrombocytopenic Purpura (TTP). </span>TTP can happen with clopidogrel tablets, sometimes after a short time (less than 2 weeks). TTP is a blood clotting problem where blood clots form in blood vessels; and can happen anywhere in the body. TTP needs to be treated in a hospital right away, because it may cause death. Get medical help right away if you have any of these symptoms and they can not be explained by another medical condition:<ul class="Disc"><li>purplish spots (called purpura) on the skin or in the mouth (mucous membranes) due to bleeding under the skin</li><li>your&nbsp;skin&nbsp;or&nbsp;the&nbsp;whites&nbsp;of&nbsp;your&nbsp;eyes&nbsp;are&nbsp;yellow&nbsp;(jaundice)</li><li>you&nbsp;feel&nbsp;tired&nbsp;or&nbsp;weak</li><li>your&nbsp;skin&nbsp;looks&nbsp;very&nbsp;pale</li><li>fever</li><li>fast&nbsp;heart&nbsp;rate&nbsp;or&nbsp;feeling&nbsp;short&nbsp;of&nbsp;breath</li><li>headache</li><li>speech&nbsp;changes</li><li>confusion</li><li>coma</li><li>stroke</li><li>seizure</li><li>low&nbsp;amount&nbsp;of&nbsp;urine,&nbsp;or&nbsp;urine&nbsp;that&nbsp;is&nbsp;pink&nbsp;or&nbsp;has&nbsp;blood&nbsp;in&nbsp;it</li><li>stomach&nbsp;area&nbsp;(abdominal)&nbsp;pain</li><li>nausea,&nbsp;vomiting,&nbsp;or&nbsp;diarrhea</li><li>vision&nbsp;changes</li></ul></li></ul><br><p>Tell&nbsp;your doctor&nbsp;if&nbsp;you&nbsp;have&nbsp;any&nbsp;side&nbsp;effect&nbsp;that&nbsp;bothers you&nbsp;or&nbsp;that&nbsp;does&nbsp;not&nbsp;go&nbsp;away.<br><br>These are not all the possible side effects of clopidogrel tablets. For more information, ask your doctor or pharmacist.<br><br>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<span class="Bold"><br><br>How should I store clopidogrel tablets?</span></p><br><ul class="Disc"><li>Store&nbsp;clopidogrel&nbsp;tablets&nbsp;at 20&deg;&nbsp;to&nbsp;25&deg;C&nbsp;(68&deg;&nbsp;to&nbsp;77&deg;F);&nbsp;excursions&nbsp;permitted&nbsp;to&nbsp;15&deg;&nbsp;to&nbsp;30&deg;C (59&deg; to 86&deg;F).</li></ul><br><p><span class="Bold">Keep&nbsp;clopidogrel&nbsp;tablets</span>&nbsp;<span class="Bold">and&nbsp;all&nbsp;medicines&nbsp;out&nbsp;of&nbsp;the&nbsp;reach&nbsp;of&nbsp;children.</span><br><br><span class="Bold">General&nbsp;information&nbsp;about&nbsp;clopidogrel&nbsp;tablets</span><br><br>Medicines are sometimes used for purposes other than those listed in a Medication Guide. Do not take clopidogrel tablets for a condition for which it was&nbsp;not prescribed. Do not give clopidogrel tablets to other people, even if they have the same symptoms that you have. They may harm them.<br><br>This Medication Guide summarizes the most important information about clopidogrel tablets. If you would like more information, talk to your doctor. Ask your doctor or pharmacist for information about clopidogrel tablets that was written for healthcare professionals.<br><br>For more information, call&nbsp;1-866-438-1985.<br><br><span class="Bold">What are&nbsp;the&nbsp;ingredients&nbsp;in&nbsp;clopidogrel&nbsp;tablets?</span><br><br><span class="Bold">Active&nbsp;ingredient:</span>&nbsp;clopidogrel&nbsp;bisulfate<span class="Bold"><br><br>Inactive&nbsp;ingredients: <br></span>crospovidone, hydrogenated castor oil, hydroxypropyl cellulose low substituted, hypromellose 15cP, iron oxide red, lactose monohydrate, mannitol, microcrystalline cellulose, polyethylene glycol 6000, titanium dioxide, and triacetin<br><br><span class="Bold">This&nbsp;Medication&nbsp;Guide&nbsp;has&nbsp;been&nbsp;approved&nbsp;by&nbsp;the&nbsp;U.S. Food&nbsp;and&nbsp;Drug&nbsp;Administration.</span><br><br>Coumadin<span class="Sup">&reg;</span>&nbsp;is&nbsp;a&nbsp;registered&nbsp;trademark&nbsp;of&nbsp;Bristol-Myers&nbsp;Squibb&nbsp;Pharma&nbsp;Company.&nbsp; <br>Prilosec<span class="Sup">&reg;</span>&nbsp;and Nexium<span class="Sup">&reg; </span>are </p><span class="Sup"></span><p>registered&nbsp;trademarks&nbsp;of&nbsp;AstraZeneca.<br>Jantoven<span class="Sup">&reg;</span>&nbsp;is&nbsp;a&nbsp;registered&nbsp;trademark&nbsp;of&nbsp;USL&nbsp;Pharma.<br><br><br><span class="Bold">GREENSTONE<span class="Sup">&reg;</span> BRAND</span><br><span class="Italics"><span class="Underline">Distributed by:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><br><span class="Bold">Greenstone LLC</span><br>Peapack, NJ 07977<br>Code No.: DRUGS/AP/19/1993<br><br>Issued: March 2012</p></div><div class="Section" data-sectionCode="51945-4"><a name="Section_19"></a><a name="section-17"></a><p></p><h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 75 mg (90 Tablet Bottle)</h1><br><p class="First"><span class="Bold">PHARMACIST: Dispense the Medication Guide</span><br><span class="Bold">provided separately to each patient.</span><br><span class="Bold">NDC </span>59762-6700-2<br><span class="Bold">90 Tablets</span><br><span class="Bold">GREENSTONE&reg; BRAND</span><br><span class="Bold">clopidogrel </span><span class="Bold">tablets, USP</span><br><span class="Bold">75 mg</span><br><span class="Bold">Rx only</span></p><br><div class="Figure"><img src="/dailymed/archives/image.cfm?archiveid=107884&type=img&name=clopidogrel-fig9.jpg" alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 75 mg (90 Tablet Bottle)"></div></div></div><div class="DataElementsTables"><table width="100%" cellPadding="3" cellSpacing="0" class="contentTablePetite"><tbody><tr><td class="contentTableTitle"><strong>CLOPIDOGREL&nbsp;							</strong><br><span class="contentTableReg">clopidogrel bisulfate tablet, film coated</span></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%"><tr><td class="formHeadingTitle" colspan="4">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Product Type</td><td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td><td class="formLabel">Item Code (Source)</td><td class="formItem">NDC:59762-6700</td></tr><tr class="formTableRow"><td class="formLabel" width="30%">Route of Administration</td><td class="formItem">ORAL</td><td class="formLabel" width="30%">DEA Schedule</td><td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;							</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td></tr><tr><td class="formTitle">Ingredient Name</td><td class="formTitle">Basis of Strength</td><td class="formTitle">Strength</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CLOPIDOGREL BISULFATE</strong> (CLOPIDOGREL) </td><td class="formItem">CLOPIDOGREL</td><td class="formItem">75&nbsp;mg</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="2">Inactive Ingredients</td></tr><tr><td class="formTitle">Ingredient Name</td><td class="formTitle">Strength</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CROSPOVIDONE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>HYDROGENATED CASTOR OIL</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>HYPROMELLOSE 2910 (15 MPA.S)</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>FERRIC OXIDE RED</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>MANNITOL</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>POLYETHYLENE GLYCOL 6000</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>TITANIUM DIOXIDE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TRIACETIN</strong></td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="4">Product Characteristics</td></tr><tr class="formTableRowAlt"><td class="formLabel">Color</td><td class="formItem">PINK</td><td class="formLabel">Score</td><td class="formItem">no score</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">ROUND (Biconvex) </td><td class="formLabel">Size</td><td class="formItem">9mm</td></tr><tr class="formTableRowAlt"><td class="formLabel">Flavor</td><td class="formItem"></td><td class="formLabel">Imprint Code</td><td class="formItem">                                                      E;34                        </td></tr><tr class="formTableRow"><td class="formLabel">Contains</td><td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="4">Packaging</td></tr><tr><td class="formTitle" width="1">#</td><td class="formTitle">Item Code</td><td class="formTitle">Package Description</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>1</strong></td><td class="formItem">NDC:59762-6700-2</td><td class="formItem">90  in 1 BOTTLE</td></tr></table></td></tr><tr><td></td></tr><tr><td class="normalizer"><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td></tr><tr><td class="formTitle">Marketing Category</td><td class="formTitle">Application Number or Monograph Citation</td><td class="formTitle">Marketing Start Date</td><td class="formTitle">Marketing End Date</td></tr><tr class="formTableRowAlt"><td class="formItem">ANDA</td><td class="formItem">ANDA090540</td><td class="formItem">05/17/2012</td><td class="formItem">03/31/2013</td></tr></table></td></tr></tbody></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Greenstone LLC							(825560733)						</td></tr></table></div><p><div class="EffectiveDate">Revised: 05/2013<div class="DocumentMetadata"><div>Document Id: 955d6d7d-485f-4b7d-8644-e9933bf35e72</div><div>Set id: 3d021d9b-c0b8-41a3-a99b-37f50d2a20ae</div><div>Version: 2</div><div>Effective Time: 20130516</div></div></div>&nbsp;<div class="DistributorName">Greenstone LLC</div></p></body></html>